0001209191-21-039727.txt : 20210610
0001209191-21-039727.hdr.sgml : 20210610
20210610213544
ACCESSION NUMBER: 0001209191-21-039727
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210609
FILED AS OF DATE: 20210610
DATE AS OF CHANGE: 20210610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Huang Jane
CENTRAL INDEX KEY: 0001683913
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36694
FILM NUMBER: 211009795
MAIL ADDRESS:
STREET 1: C/O MOURANT OZANNES CORPORATE SERVICES
STREET 2: 94 SOLARIS AVENUE
CITY: CAMANA BAY, GRAND CAYMAN
STATE: E9
ZIP: KY1-1108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001359931
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 204580525
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 646-844-0337
MAIL ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
FORMER COMPANY:
FORMER CONFORMED NAME: ArTara Therapeutics, Inc.
DATE OF NAME CHANGE: 20200110
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEON THERAPEUTICS INC
DATE OF NAME CHANGE: 20060420
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-06-09
0
0001359931
Protara Therapeutics, Inc.
TARA
0001683913
Huang Jane
C/O PROTARA THERAPEUTICS, INC.
345 PARK AVENUE SOUTH, 3RD FLOOR
NEW YORK
NY
10010
1
0
0
0
Stock Option (Right to Buy)
10.51
2021-06-09
4
A
0
20000
0.00
A
2031-06-08
Common Stock
20000
20000
D
Stock Option (Right to Buy)
10.51
2021-06-09
4
A
0
10000
0.00
A
2031-06-08
Common Stock
10000
10000
D
The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
/s/ Karen Deschaine, Attorney-in-Fact
2021-06-10